{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:51:20Z","timestamp":1795042280766,"version":"4.10.2"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Aflibercept biosimilars can expand available treatment options in retinal diseases and have the potential to improve patient access to safe and effective therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To establish equivalence in efficacy and similarity in safety, pharmacokinetics, and immunogenicity of SB15 and reference aflibercept (AFL) in neovascular age-related macular degeneration (nAMD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a randomized double-masked parallel group phase 3 trial conducted at 56 centers in 10 countries from June 2020 to March 2022, including follow-up through 56 weeks. Of 549 screened participants, 449 participants 50 years and older with treatment-naive nAMD were included and randomly assigned to SB15 (n\u2009=\u2009224) or AFL (n\u2009=\u2009225). Key exclusion criteria included considerable scarring, fibrosis, atrophy, and hemorrhage. This report includes results up to the end of the parallel group period at week 32. Of the 449 randomized participants, 438 (97.6%) completed week 32 follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were randomized 1:1 to receive 2 mg of SB15 or AFL every 4 weeks for the first 12 weeks (3 injections), followed by dosing every 8 weeks up to week 48, with final assessments at week 56.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was the change in best-corrected visual acuity (BCVA) from baseline to week 8 with predefined equivalence margins of \u22123 letters to 3 letters. Other key end points were changes in BCVA and central subfield thickness up to week 32, safety, pharmacokinetics, and immunogenicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean (SD) age among the 449 included participants was 74.0 (8.1) years, and 250 participants (55.7%) were female. Baseline demographic characteristics and most disease characteristics were comparable between treatment groups. The least squares mean change in BCVA from baseline to week 8 in the SB15 group was equivalent to that in the AFL group (6.7 letters vs 6.6 letters, respectively; difference, 0.1 letters; 95% CI, \u22121.3 to 1.4). Comparable efficacy between treatment groups was maintained up to week 32 (least squares mean change from baseline in BCVA: SB15, 7.6 letters vs AFL, 6.5 letters; least squares mean change from baseline in central subfield thickness: SB15, \u2212110.4 \u03bcm vs AFL, \u2212115.7 \u03bcm). No clinically relevant differences were observed in the incidence of treatment-emergent adverse events (TEAEs) (SB15, 107\/224 [47.8%] vs AFL, 98\/224 [43.8%]) and ocular TEAEs in the study eye (SB15, 41\/224 [18.3%] vs AFL, 28\/224 [12.5%]). The serum concentration profiles and cumulative incidences of overall antidrug antibody positive participants were comparable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this phase 3 randomized clinical trial, SB15 and AFL showed equivalent efficacy and comparable safety, pharmacokinetics, and immunogenicity in participants with nAMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04450329\">NCT04450329<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.2260","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T15:01:07Z","timestamp":1686236467000},"page":"668","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"141","author":[{"given":"Se Joon","family":"Woo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bradvica","sequence":"additional","affiliation":[{"name":"Clinical of Ophthalmology, Osijek University Hospital, Faculty of Medicine University of Osijek, Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Vajas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Clinical Center, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Axon Clinical, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Studnicka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[{"name":"Ophthalmology Clinic, Univerzity Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles Univerzity, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wylegala","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Gabinet Okulistyczny, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[{"name":"Retina Research Institute of Texas, Abilen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolmin","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Korea University Ansan Hospital, Ansan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Orski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rydygier Memorial Hospital, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Astakhov","sequence":"additional","affiliation":[{"name":"Pavlov First State Medical University of St Petersburg, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"T\u00f3th-Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Albert Szent-Gy\u00f6rgyi Medical Center, University of Szeged, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Csutak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of P\u00e9cs Medical School, P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Enyedi","sequence":"additional","affiliation":[{"name":"Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Oh","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyerin","family":"Jang","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Doheny Eye Institute, Pasadena, California"},{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi230029r1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/issn.0250-3751","article-title":"Neovascular age-related macular degeneration.","volume":"55","author":"Shao","year":"2016","journal-title":"Dev Ophthalmol"},{"issue":"6","key":"eoi230029r2","doi-asserted-by":"publisher","first-page":"1227.e1","DOI":"10.1016\/j.ophtha.2009.01.008","article-title":"VEGF and age-related macular degeneration.","volume":"116","author":"McKay","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230029r3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA).","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"5","key":"eoi230029r4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","article-title":"Retinal vein occlusion (RVO) guideline: executive summary.","volume":"36","author":"Nicholson","year":"2022","journal-title":"Eye (Lond)"},{"key":"eoi230029r5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"Suppl 1","key":"eoi230029r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00347-018-0810-1","article-title":"Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration.","volume":"116","author":"Professional Association of German Ophthalmologists","year":"2019","journal-title":"Ophthalmologe"},{"key":"eoi230029r7","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.2147\/OPTH","article-title":"Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.","volume":"9","author":"Balaratnasingam","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"14","key":"eoi230029r13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi230029r14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi230029r15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi230029r16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study.","volume":"124","author":"Heier","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"eoi230029r17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration.","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230029r18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial.","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi230029r19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"10326","key":"eoi230029r20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"eoi230029r22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi230029r24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bcp.2011.72.issue-3","article-title":"A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.","volume":"72","author":"Thai","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"eoi230029r8","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Accessed September 19, 2022, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf"},{"key":"eoi230029r9","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Accessed October 27, 2022, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf"},{"key":"eoi230029r10","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Accessed September 19, 2022, https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"eoi230029r11","unstructured":"Sagong? M, Lee? H, Huh? J, . Analytical similarity assessment of an aflibercept biosimilar SB15 to its commercially available reference product (Eylea). BioSpace. Published April 24, 2023. Accessed May 3, 2023. https:\/\/www.biospace.com\/article\/releases\/1-year-outcomes-of-phase-3-study-for-sb15-proposed-biosimilar-to-eylea-aflibercept-presented-at-the-2023-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting\/"},{"key":"eoi230029r12","unstructured":"American Academy of Ophthalmology. The use of biosimilars in ophthalmic practice\u20142022. Accessed May 3, 2023. https:\/\/www.aao.org\/clinical-statement\/use-of-biosimilars-in-ophthalmic-practice"},{"key":"eoi230029r21","unstructured":"US Food and Drug Administration. Neovascular age-related macular degeneration: developing drugs for treatment\u2014guidance for industry. Accessed April 7, 2023. https:\/\/www.fda.gov\/media\/165606\/download"},{"key":"eoi230029r23","unstructured":"US Food and Drug Administration. Aflibercept\u2014prescribing information. Accessed October 04, 2022, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125387s076lbl.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2805760\/jamaophthalmology_woo_2023_oi_230029_1688590002.45271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T15:51:34Z","timestamp":1689868294000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2805760"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2260","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}